UNLABELLED: This study evaluates cytokines production in bone and bone marrow of patients with an osteoporotic fracture or with osteoarthritis by real time PCR, Western blot and immunohistochemistry. We demonstrate that the cytokine pattern is shifted towards osteoclast activation and osteoblast inhibition in patients with osteoporotic fractures. INTRODUCTION: Fragility fractures are the resultant of low bone mass and poor bone architecture typical of osteoporosis. Cytokines involved in the control of bone cell maturation and function are produced by both bone itself and bone marrow cells, but the roles of these two sources in its control and the amounts they produce are not clear. This study compares their production in patients with an osteoporotic fracture and those with osteoarthritis. METHODS: We evaluated 52 femoral heads from women subjected to hip-joint replacement surgery for femoral neck fractures due to low-energy trauma (37), or for osteoarthritis (15). Total RNA was extracted from both bone and bone marrow, and quantitative PCR was used to identify the receptor activator of nuclear factor kB Ligand (RANKL), osteoprotegerin (OPG), macrophage colony stimulating factor (M-CSF), transforming growth factor β (TGFβ), Dickoppf-1 (DKK-1) and sclerostin (SOST) expression. Immunohistochemistry and Western blot were performed in order to quantify and localize in bone and bone marrow the cytokines. RESULTS: We found an increase of RANKL/OPG ratio, M-CSF, SOST and DKK-1 in fractured patients, whereas TGFβ was increased in osteoarthritic bone. Bone marrow produced greater amounts of RANKL, M-CSF and TGFβ compared to bone, whereas the production of DKK-1 and SOST was higher in bone. CONCLUSIONS: We show that bone marrow cells produced the greater amount of pro-osteoclastogenic cytokines, whereas bone cells produced higher amount of osteoblast inhibitors in patients with fragility fracture, thus the cytokine pattern is shifted towards osteoclast activation and osteoblast inhibition in these patients.
UNLABELLED: This study evaluates cytokines production in bone and bone marrow of patients with an osteoporotic fracture or with osteoarthritis by real time PCR, Western blot and immunohistochemistry. We demonstrate that the cytokine pattern is shifted towards osteoclast activation and osteoblast inhibition in patients with osteoporotic fractures. INTRODUCTION:Fragility fractures are the resultant of low bone mass and poor bone architecture typical of osteoporosis. Cytokines involved in the control of bone cell maturation and function are produced by both bone itself and bone marrow cells, but the roles of these two sources in its control and the amounts they produce are not clear. This study compares their production in patients with an osteoporotic fracture and those with osteoarthritis. METHODS: We evaluated 52 femoral heads from women subjected to hip-joint replacement surgery for femoral neck fractures due to low-energy trauma (37), or for osteoarthritis (15). Total RNA was extracted from both bone and bone marrow, and quantitative PCR was used to identify the receptor activator of nuclear factor kB Ligand (RANKL), osteoprotegerin (OPG), macrophage colony stimulating factor (M-CSF), transforming growth factor β (TGFβ), Dickoppf-1 (DKK-1) and sclerostin (SOST) expression. Immunohistochemistry and Western blot were performed in order to quantify and localize in bone and bone marrow the cytokines. RESULTS: We found an increase of RANKL/OPG ratio, M-CSF, SOST and DKK-1 in fracturedpatients, whereas TGFβ was increased in osteoarthritic bone. Bone marrow produced greater amounts of RANKL, M-CSF and TGFβ compared to bone, whereas the production of DKK-1 and SOST was higher in bone. CONCLUSIONS: We show that bone marrow cells produced the greater amount of pro-osteoclastogenic cytokines, whereas bone cells produced higher amount of osteoblast inhibitors in patients with fragility fracture, thus the cytokine pattern is shifted towards osteoclast activation and osteoblast inhibition in these patients.
Authors: Ralph A Meyer; Martha H Meyer; Mark Tenholder; Sharon Wondracek; Ruth Wasserman; Patricia Garges Journal: J Bone Joint Surg Am Date: 2003-07 Impact factor: 5.284
Authors: Heiner Appel; Gisela Ruiz-Heiland; Joachim Listing; Jochen Zwerina; Martin Herrmann; Ruediger Mueller; Hildrun Haibel; Xenofon Baraliakos; Axel Hempfing; Martin Rudwaleit; Joachim Sieper; Georg Schett Journal: Arthritis Rheum Date: 2009-11
Authors: J Velasco; M T Zarrabeitia; J R Prieto; J L Perez-Castrillon; M D Perez-Aguilar; M I Perez-Nuñez; C Sañudo; J Hernandez-Elena; I Calvo; F Ortiz; J Gonzalez-Macias; J A Riancho Journal: Osteoporos Int Date: 2009-04-17 Impact factor: 4.507
Authors: Alexander Grundt; Ingo Alexander Grafe; Ute Liegibel; Ulrike Sommer; Peter Nawroth; Christian Kasperk Journal: Biochem Biophys Res Commun Date: 2009-09-11 Impact factor: 3.575
Authors: P D'Amelio; C Tamone; F Sassi; L D'Amico; I Roato; S Patanè; M Ravazzoli; L Veneziano; R Ferracini; G P Pescarmona; G C Isaia Journal: Osteoporos Int Date: 2011-05-27 Impact factor: 4.507
Authors: Maria José Franco-Barrera; Maria Guadalupe Zavala-Cerna; Georgina Aguilar-Portillo; Diana Brisa Sánchez-Gomez; Olivia Torres-Bugarin; Miguel Angel Franco-Barrera; Carlos Manuel Roa-Encarnacion Journal: Clin Rev Allergy Immunol Date: 2017-02 Impact factor: 8.667
Authors: Jesús Delgado-Calle; Carolina Sañudo; Agustín F Fernández; Raúl García-Renedo; Mario F Fraga; José A Riancho Journal: Epigenetics Date: 2012-01-01 Impact factor: 4.528
Authors: Andrea Z LaCroix; Rebecca D Jackson; Aaron Aragaki; Charles Kooperberg; Jane A Cauley; Zhao Chen; Meryl S Leboff; David Duggan; Jean Wactawski-Wende Journal: Bone Date: 2013-06-02 Impact factor: 4.398